Abcam to Open Office in Shanghai
News Jan 21, 2014
Abcam plc has announced that it will open a new office in February 2014, in Shanghai, China. The new hub is the Company’s ninth global office, and has been established to support Abcam’s focus on increasing geographic reach and improving distribution channels to rapidly growing markets. Located in Zhangjiang Hi-Tech Park, Pudong New District, a prominent economic growth and innovation area, the office is within close proximity of the City and Abcam’s production facility in Hangzhou, which develops pioneering research tools such as RabMAb®, its proprietary rabbit monoclonal antibody technology.
The office will house customer and technical support functions, provided by native Mandarin speakers, as well as a product warehouse, which will facilitate local stock storage for the first time. This means that customers will benefit from improved delivery times, with the large majority of orders arriving at their door within 24 hours. The proximity of the office will also enable Abcam to support customers with more specific needs through its extensive range of products and services, including custom antibody production.
Dr Jonathan Milner, CEO, Abcam, said: “China is an important market for Abcam and we’re pleased to provide enhanced services such as faster delivery and dedicated local language support to our customers. Further future investments will ensure we continue to deliver innovative products and services to enable scientists to discover more.”
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.